Herpes zoster during treatment with arsenic trioxide.
Lanska
Douglas J
DJ
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000009:adverse effects* / Q000627:therapeutic use; D006562:Herpes Zoster / Q000139:chemically induced* / Q000453:epidemiology; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy / Q000821:virology; D010087:Oxides / Q000009:adverse effects* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D000077237:Arsenic Trioxide